Inverse Monocytic Subset Profile in Blood and Tissue During Human Heart Transplant Rejection With a Simultaneous Predominance of M2 Macrophages at the Tissue Level

2015 ◽  
Vol 34 (4) ◽  
pp. S295
Author(s):  
T.P. van den Bosch ◽  
M.D. Kraaij ◽  
K. Caliskan ◽  
A.A. Constantinescu ◽  
O.C. Manintveld ◽  
...  
2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Jian Lu ◽  
Weiwei Wang ◽  
Peiyuan Li ◽  
Xiaodong Wang ◽  
Chao Gao ◽  
...  

AbstractRegulatory T cells (Tregs), which characteristically express forkhead box protein 3 (Foxp3), are essential for the induction of immune tolerance. Here, we investigated microRNA-146a (miR-146a), a miRNA that is widely expressed in Tregs and closely related to their homeostasis and function, with the aim of enhancing the function of Tregs by regulating miR-146a and then suppressing transplant rejection. The effect of the absence of miR-146a on Treg function in the presence or absence of rapamycin was detected in both a mouse heart transplantation model and cell co-cultures in vitro. The absence of miR-146a exerted a mild tissue-protective effect by transiently prolonging allograft survival and reducing the infiltration of CD4+ and CD8+ T cells into the allografts. Meanwhile, the absence of miR-146a increased Treg expansion but impaired the ability of Tregs to restrict T helper cell type 1 (Th1) responses. A miR-146a deficiency combined with interferon (IFN)-γ blockade repaired the impaired Treg function, further prolonged allograft survival, and alleviated rejection. Importantly, miR-146a regulated Tregs mainly through the IFN-γ/signal transducer and activator of transcription (STAT) 1 pathway, which is implicated in Treg function to inhibit Th1 responses. Our data suggest miR-146a controls a specific aspect of Treg function, and modulation of miR-146a may enhance Treg efficacy in alleviating heart transplant rejection in mice.


1994 ◽  
Vol 40 ◽  
pp. 8
Author(s):  
S. Sheldon ◽  
P. Haselton ◽  
N.A. Yonan ◽  
A.N. Rahman ◽  
A.K. Deiraniya ◽  
...  

Gene Therapy ◽  
2001 ◽  
Vol 8 (22) ◽  
pp. 1738-1744 ◽  
Author(s):  
JL Bracy ◽  
CM Chase ◽  
PS Russell ◽  
S Mauiyyedi ◽  
RB Colvin ◽  
...  

1993 ◽  
Vol 16 (5_suppl) ◽  
pp. 168-172 ◽  
Author(s):  
R. Dall'Amico ◽  
F. Zulian ◽  
G. Montini ◽  
B. Andretta ◽  
L. Murer ◽  
...  

Photopheresis (ECP) is a new therapy for oncological and autoimmune diseases consisting in the reinfusion of 3-9x 109 leukocytes, taken from the patient by leukapheresis, and treated in an extracorporeal system with 8-methoxypsoralen and ultraviolet light A. Nine patients affected by T cell immunomediated diseases (2 scleroderma, 1 chronic GVHD, 1 polyarteritis, 1 rheumatoid arthritis and 4 heart transplant patients with numerous episodes of acute rejection) were treated with ECP. Photopheresis was performed on 2 consecutive days every 3-4 weeks. All patients affected by autoimmune diseases experienced an improvement during treatment with ECP. In 2 of the 4 patients with heart transplant, rejection was reversed by photopheresis. No major side effects were observed during the treatment. In conclusion ECP is a safe and well tolerated therapy. Although the number of patients is small, ECP seems to be an effective modality in many diseases.


BMJ ◽  
1976 ◽  
Vol 1 (6012) ◽  
pp. 749-750 ◽  
Author(s):  
A S Coulson ◽  
V H Zeitman ◽  
E B Stinson ◽  
R B Griepp ◽  
C P Bieber ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document